{"gene":"BCKDK","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2014,"finding":"BCKDK phosphorylates the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKD), inactivating it; loss-of-function mutations in BCKDK (p.L389P and p.R174Gfs1*) result in total loss of kinase activity, undetectable phospho-E1α, increased BCKD activity, and rapid BCAA catabolism, demonstrated in patient-derived fibroblasts.","method":"Functional analysis of missense and frameshift mutations in patient fibroblasts; measurement of kinase activity and phospho-E1α levels by western blot","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct kinase activity assay with loss-of-function mutations, orthogonal biochemical readouts (phospho-E1α, BCKD activity), single lab but multiple methods","pmids":["24449431"],"is_preprint":false},{"year":2017,"finding":"BCKDK promotes colorectal cancer tumorigenesis through direct phosphorylation of MEK, activating the MAPK signaling pathway, independently of its role in BCAA catabolism; this was shown by co-immunoprecipitation and western blot in CRC cells, and inhibited by the BCKDK inhibitor phenyl butyrate.","method":"Co-immunoprecipitation, western blot, in vitro kinase assay, cell transformation assays, xenograft models","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct MEK phosphorylation shown by Co-IP and western blot, single lab, limited orthogonal validation of direct kinase activity on MEK","pmids":["28501528"],"is_preprint":false},{"year":2019,"finding":"UBE3B (an E3 ubiquitin ligase mutated in Kaufman oculocerebrofacial syndrome) ubiquitinates BCKDK in vivo; BCKDK was identified as a substrate of UBE3B, linking UBE3B loss to perturbation of BCAA metabolic pathways and mitochondrial respiration.","method":"In vivo substrate identification (Ube3b knockout mice), Co-immunoprecipitation, metabolomics profiling of plasma and cortex","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and in vivo mouse model with defined metabolic phenotype, single lab with multiple orthogonal approaches","pmids":["30808755"],"is_preprint":false},{"year":2020,"finding":"Src kinase phosphorylates BCKDK at tyrosine 246 (Y246) in vitro and in cellulo; this phosphorylation enhances BCKDK kinase activity and protein stability, promoting CRC cell migration, invasion, and EMT. Knockdown/knockout of Src reduced BCKDK Y246 phosphorylation.","method":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis (Y246 phospho-dead mutant), Src knockdown/knockout, phosphoproteomics","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, validated in cellulo by Src KO/KD, phosphoproteomics, multiple orthogonal methods in single lab","pmids":["32238881"],"is_preprint":false},{"year":2020,"finding":"Aminopeptidase N (APN/CD13) mediates phosphorylation of BCKDK at serine 31 (S31); phosphorylated BCKDK then interacts with ERK1/2 and phosphorylates it, thereby activating the ERK signaling pathway in hepatocellular carcinoma cells.","method":"Phosphoproteomics, co-immunoprecipitation, proximity ligation assay, point mutation analysis, western blot, APN knockout in vitro and in vivo","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and proximity ligation assay plus point mutation, multiple methods in single lab","pmids":["32457292"],"is_preprint":false},{"year":2021,"finding":"BCKDK serves as a compensatory kinase for PDK1-4 (pyruvate dehydrogenase kinases) during embryonic development; in quadruple Pdk knockout embryos, PDC (pyruvate dehydrogenase complex) remained phosphorylated, and additional knockout of Bckdk eliminated PDC phosphorylation, increased PDC activity and pyruvate entry into the TCA cycle, and caused embryonic lethality.","method":"Sequential gene knockout (mouse models), PDC activity assay, phosphorylation status assessment by western blot","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic epistasis with in vivo reconstitution-style validation (Pdk total KO + Bckdk KO), direct enzymatic activity assay, multiple KO lines confirming compensatory function","pmids":["33773101"],"is_preprint":false},{"year":2021,"finding":"BCKDK inhibition in triple-negative breast cancer reduces intracellular BCKAs, downregulates mitochondrial metabolism genes, reduces electron transport chain complex protein expression, oxygen consumption, and ATP production, and upregulates sestrin 2 while decreasing mTORC1 signaling and protein synthesis.","method":"Genetic silencing (siRNA/shRNA) and pharmacological inhibition of BCKDK, metabolite measurement, transcriptome analysis, mitochondrial respiration assays, mTORC1 signaling assessment","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological inhibition with multiple functional readouts (metabolites, respiration, signaling), single lab","pmids":["34526485"],"is_preprint":false},{"year":2022,"finding":"Loss-of-function mutation in BCKDK (p.Thr334del) causes hyperactivity of BCKDH and BCAA over-consumption, demonstrated by functional transfection assays in cells; BCKDK phosphorylation-mediated inactivation of BCKDH was thus directly shown to be the molecular mechanism of BCAA homeostasis in human disease.","method":"Cell transfection with mutant BCKDK construct, functional BCKDH activity assay, plasma and CSF metabolite measurement","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct enzymatic activity assay in transfected cells, single lab, single method","pmids":["35216372"],"is_preprint":false},{"year":2023,"finding":"BCKDK inhibits TRIM21-mediated ubiquitination and degradation of talin1 in breast cancer; BCKDK interaction with talin1 was shown, and BCKDK prevented TRIM21-talin1 binding, thereby stabilizing talin1, activating the FAK/MAPK pathway, and promoting focal adhesion assembly and cell migration.","method":"Co-immunoprecipitation, western blot, loss-of-function (shRNA knockdown), in vitro migration assays, in vivo lung metastasis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing BCKDK-talin1 and BCKDK-TRIM21 interaction with functional KD and in vivo validation, single lab","pmids":["37460470"],"is_preprint":false},{"year":2024,"finding":"BCKDK phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability; BCKDK also phosphorylates STUB1 (E3 ubiquitin ligase of BCAT1) at S19, disrupting STUB1-BCAT1 interaction and preventing BCAT1 ubiquitin-mediated degradation, thereby promoting GBM proliferation.","method":"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, mass spectrometry, in vivo xenograft experiments","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis at multiple sites, mass spectrometry, Co-IP, and in vivo validation, multiple orthogonal methods","pmids":["38621458"],"is_preprint":false},{"year":2024,"finding":"BCKDK interacts with glucose-6-phosphate dehydrogenase (G6PD) and increases flux through the pentose phosphate pathway; forced G6PD expression rescued growth defects in BCKDK-deficient TNBC cells, placing BCKDK upstream of G6PD in metabolic reprogramming.","method":"Co-immunoprecipitation, mass spectrometry, isotope tracer studies, immunofluorescence, rescue (G6PD overexpression), cell viability assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, isotope tracing, and genetic rescue in single lab with multiple orthogonal methods","pmids":["39025830"],"is_preprint":false},{"year":2024,"finding":"BCKDK interacts with the NDUFS1 subunit of mitochondrial Complex I to stabilize its function; loss of BCKDK disrupts this interaction, leading to Complex I destabilization, reduced membrane potential, increased ROS, and promotion of α-synuclein oligomerization and aggregation in dopaminergic neurons.","method":"Co-immunoprecipitation, mitochondrial membrane potential assay, ROS measurement, BCKDK knockdown/restoration in neuron-like cells and patient-derived iPS-derived dopaminergic neurons","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying NDUFS1 interaction, rescue experiments restoring Complex I activity, validated in patient-derived cells, single lab","pmids":["39709505"],"is_preprint":false},{"year":2024,"finding":"BCKDK interacts with BCLAF1 and promotes its phosphorylation at serine 285; this modification enables BCLAF1 to bind the MYC promoter and enhance MYC transcription, which upregulates hexokinase 2 (HK2) to promote aerobic glycolysis and lung cancer progression and Trametinib resistance.","method":"Co-immunoprecipitation, western blot, chromatin immunoprecipitation, luciferase reporter assay, point mutation, RNA sequencing, cell-based functional assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, luciferase, and phospho-site mutation in single lab with multiple orthogonal methods","pmids":["40442441"],"is_preprint":false},{"year":2024,"finding":"Nuclear-localized BCKDK phosphorylates RNF8 at Ser157, preventing ubiquitin-mediated degradation of RAD51, thereby facilitating homologous recombination repair (HRR) and promoting resistance to DNA damage-inducing therapy in breast cancer; this function is independent of BCKDK's metabolic role.","method":"Subcellular fractionation/localization (nuclear BCKDK), Co-IP, site-directed mutagenesis, RAD51 ubiquitination assay, HR repair functional assay, pharmacological inhibition","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation of RNF8 shown with site mutagenesis, Co-IP, and functional HR assay, nuclear localization by fractionation, single lab","pmids":["40298908"],"is_preprint":false},{"year":2024,"finding":"Fyn tyrosine kinase phosphorylates BCKDK at Y151, increasing its catalytic activity and protein stability, promoting GBM cell proliferation; elevated BCKDK also increases N-acetyl-L-alanine (NAAL) levels, which activates ERK signaling and promotes proliferation; silencing BCKDK increases ACY1 expression.","method":"In vitro and in vivo kinase assay, site-directed mutagenesis (Y151), metabolite profiling, western blot, tumor xenograft model","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with mutagenesis, metabolite profiling, single lab","pmids":["39170503"],"is_preprint":false},{"year":2024,"finding":"The BCKDK inhibitor BT2 acts as a mitochondrial uncoupler independently of its inhibitory effect on BCKDK; BT2 increases proton conductance across the mitochondrial inner membrane, lowering mitochondrial ROS production and de novo lipogenesis, as confirmed using patch-clamp electrophysiology and oxygen consumption measurements, and was active even in Bckdk-/- animals.","method":"Oxygen consumption measurement, mitochondrial membrane potential assay, patch-clamp electrophysiology, Bckdk knockout mouse model, de novo lipogenesis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal direct methods (patch-clamp, respiration, membrane potential), confirmed in knockout animals to isolate off-target effect, single lab but rigorous multi-method study","pmids":["38301896"],"is_preprint":false},{"year":2024,"finding":"PSMD14 deubiquitinase directly interacts with and deubiquitinates BCKDK, antagonizing TRIM21-mediated proteasomal degradation of BCKDK, thereby stabilizing BCKDK protein levels in GBM cells.","method":"Co-immunoprecipitation, deubiquitination assay, PSMD14 knockdown, western blot","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and deubiquitination assay identifying PSMD14-BCKDK interaction and TRIM21 as E3 ligase, single lab","pmids":["41876842"],"is_preprint":false},{"year":2024,"finding":"BT2 (a BCKDK allosteric inhibitor) activates BCAA oxidation via inhibition of BCKDK, but also independently reduces plasma tryptophan by binding serum albumin and displacing tryptophan, releasing it for catabolism to kynurenine; this was demonstrated using Bckdk-/- mice (where BT2 could not activate BCAA oxidation but still depleted tryptophan), equilibrium dialysis, and albumin-deficient mice.","method":"Bckdk-/- mouse model, equilibrium dialysis, albumin-knockout mice, metabolite profiling","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous use of Bckdk-/- mice to isolate on-target vs off-target effects, orthogonal validation with equilibrium dialysis and albumin-KO mice, mechanistically definitive","pmids":["38496495"],"is_preprint":true},{"year":2025,"finding":"BT2 activates BCAA oxidation through BCKDK inhibition, but also independently reduces plasma tryptophan by binding serum albumin and displacing tryptophan; this off-target effect was confirmed in Bckdk-/- mice by equilibrium dialysis and albumin-deficient mice (peer-reviewed version of preprint 38496495).","method":"Bckdk-/- mouse model, equilibrium dialysis, albumin-knockout mice, plasma metabolite profiling","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods, confirmed in multiple genetic mouse models, peer-reviewed replication of preprint findings","pmids":["40348014"],"is_preprint":false},{"year":2025,"finding":"In zebrafish, Bckdk acts as a post-translational regulator of the maternal-to-zygotic transition (MZT); Bckdk depletion reduces phosphorylation of Phf10/Baf45a (a BAF chromatin remodeling subunit), and expression of a phospho-mimetic Phf10 rescued epiboly defects and ZGA abnormalities caused by bckdk knockdown, placing BCKDK upstream of Phf10-mediated chromatin remodeling during MZT.","method":"CRISPR-RfxCas13d mRNA knockdown screen in zebrafish, phospho-proteomics, phf10 mRNA knockdown, phospho-mimetic Phf10 rescue, H3K27ac measurement","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — epistasis via phospho-mimetic rescue, phospho-proteomics identifying substrate, functional developmental readout, multiple orthogonal methods in single study","pmids":["41254269"],"is_preprint":false},{"year":2024,"finding":"PRSS55 interacts with BCKDK and its substrate BCKDHA in mouse testes/sperm, as validated by co-immunoprecipitation and LC-MS/MS; loss of Prss55 results in accumulation of BCAAs in testes, suggesting PRSS55 modulates BCKDK-mediated BCAA catabolism in the context of sperm mitochondrial function.","method":"Co-immunoprecipitation, LC-MS/MS, Prss55-/- mouse model, metabolomics, mitochondrial function assays","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and LC-MS/MS validating interaction, metabolomics and functional assays in KO mouse, single lab","pmids":["41444608"],"is_preprint":false},{"year":2016,"finding":"In BCKDK-deficient patient fibroblasts, loss of BCKDK increases superoxide anion production (2-fold), reduces ATP-linked respiration and intracellular ATP levels (to ~60%), and causes mitochondrial hyperfusion associated with changes in OPA1 and mitofusin 2/MFN2 forms; BCKDK knockdown in control fibroblasts recapitulated these mitochondrial phenotypes.","method":"Bioenergetics assays (oxygen consumption, ATP measurement), superoxide measurement, ultrastructural analysis (electron microscopy), western blot (OPA1, MFN2), siRNA knockdown","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple direct mitochondrial functional assays in patient cells and siRNA knockdown confirmation, single lab","pmids":["26809120"],"is_preprint":false},{"year":2024,"finding":"In BCKDK-deficient mice, genetic re-regulation of BCAA catabolism via Dbt haploinsufficiency (reducing downstream catabolic flux) partially rescues biochemical and behavioral phenotypes, demonstrating that aberrant flux through the BCAA catabolic pathway (not just BCAA insufficiency) contributes to pathology.","method":"Mouse model of BCKDK deficiency, Dbt haploinsufficiency genetic epistasis, behavioral testing, plasma metabolite measurement","journal":"Molecular genetics and metabolism reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in mouse model with biochemical and behavioral rescue readouts, single lab","pmids":["38770403"],"is_preprint":false},{"year":2025,"finding":"In BCKDK-deficient mouse brains (but not skeletal muscle), fasting activates the integrated stress response (ISR) with upregulation of Atf4 and its targets including Slc7a5; stable isotope tracing showed lower BCAA-derived nitrogen delivery to brain glutamate in BCKDK KO mice, demonstrating a brain-specific metabolic vulnerability.","method":"Bckdk KO mouse model, stable isotope tracing with mass spectrometry imaging, protein synthesis measurement, ISR marker quantification (ATF4, target genes), mTORC1 signaling assessment","journal":"The Journal of nutritional biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isotope tracing with mass spectrometry imaging, KO mouse model, multiple orthogonal pathway readouts, single lab","pmids":["41587643"],"is_preprint":false}],"current_model":"BCKDK is a mitochondria-associated kinase that canonically phosphorylates and inactivates the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby restraining BCAA catabolism; beyond this metabolic role, BCKDK also phosphorylates MEK, ERK1/2, RNF8, BCAT1, STUB1, BCLAF1, and Phf10 to regulate MAPK signaling, homologous recombination repair, chromatin remodeling during embryonic development, and cancer cell metabolism, and is itself regulated by phosphorylation from upstream kinases (Src at Y246, Fyn at Y151, APN-mediated at S31) and by ubiquitination via TRIM21 (antagonized by PSMD14), with its protein stability and activity controlled by these post-translational modifications."},"narrative":{"mechanistic_narrative":"BCKDK is a mitochondria-associated protein kinase that controls branched-chain amino acid (BCAA) catabolism by phosphorylating and inactivating the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDH), with loss-of-function mutations abolishing E1α phosphorylation, derepressing BCKDH activity, and driving rapid BCAA over-consumption in patients [PMID:24449431, PMID:35216372]. Its metabolic reach extends beyond BCKDH: BCKDK acts as a compensatory kinase for the pyruvate dehydrogenase complex during embryogenesis, and its combined loss with the pyruvate dehydrogenase kinases eliminates PDC phosphorylation and is embryonic-lethal [PMID:33773101]. Loss of BCKDK perturbs mitochondrial bioenergetics, increasing superoxide production, lowering ATP-linked respiration, and altering mitochondrial morphology [PMID:26809120], and BCKDK physically stabilizes the Complex I subunit NDUFS1, with its loss promoting α-synuclein aggregation in dopaminergic neurons [PMID:39709505]. In disease tissue, BCKDK functions as a signaling kinase independent of BCAA metabolism, directly phosphorylating MEK and ERK1/2 to activate MAPK signaling [PMID:28501528, PMID:32457292], phosphorylating BCAT1 and STUB1 to stabilize BCAT1 and drive glioblastoma growth [PMID:38621458], phosphorylating BCLAF1 to enhance MYC-driven glycolysis [PMID:40442441], and — from a nuclear pool — phosphorylating RNF8 to protect RAD51 and promote homologous recombination repair [PMID:40298908]. BCKDK is itself regulated by post-translational modification: Src (Y246) and Fyn (Y151) phosphorylation enhance its activity and stability [PMID:32238881, PMID:39170503], UBE3B and TRIM21 ubiquitinate it while PSMD14 deubiquitinates and stabilizes it [PMID:30808755, PMID:41876842], and BCKDK reciprocally protects substrates such as talin1 from TRIM21-mediated degradation [PMID:37460470]. The small-molecule inhibitors BT2 and phenylbutyrate inhibit BCKDK, but BT2 also acts off-target as a mitochondrial uncoupler and albumin-tryptophan displacer independently of BCKDK [PMID:38301896, PMID:40348014]. A zebrafish study additionally places Bckdk upstream of Phf10/BAF chromatin remodeling during the maternal-to-zygotic transition [PMID:41254269].","teleology":[{"year":2014,"claim":"Established that BCKDK is the physiological kinase that restrains BCAA catabolism by phosphorylating and inactivating BCKDH E1α, resolving how BCAA homeostasis is set in humans.","evidence":"Functional analysis of loss-of-function mutations (p.L389P, p.R174Gfs1*) in patient fibroblasts with kinase activity and phospho-E1α readouts","pmids":["24449431"],"confidence":"High","gaps":["Did not address non-metabolic substrates","No structural basis for E1α recognition"]},{"year":2016,"claim":"Showed BCKDK loss has broad mitochondrial consequences beyond BCAA flux, linking it to redox balance, bioenergetics, and mitochondrial dynamics.","evidence":"Bioenergetics, superoxide and EM analysis in BCKDK-deficient patient fibroblasts plus siRNA knockdown","pmids":["26809120"],"confidence":"Medium","gaps":["Mechanism linking BCKDK loss to OPA1/MFN2 changes unresolved","Whether effects are metabolic or direct unclear"]},{"year":2017,"claim":"First evidence that BCKDK has a metabolism-independent signaling function, directly phosphorylating MEK to activate MAPK in cancer.","evidence":"Co-IP, in vitro kinase assay, transformation and xenograft assays in CRC cells","pmids":["28501528"],"confidence":"Medium","gaps":["Direct MEK phosphorylation not independently confirmed","Phospho-site on MEK not defined"]},{"year":2019,"claim":"Identified BCKDK as a ubiquitination substrate of UBE3B, establishing post-translational control of its abundance and a disease link.","evidence":"Reciprocal Co-IP and metabolomics in Ube3b knockout mice","pmids":["30808755"],"confidence":"Medium","gaps":["Ubiquitination site not mapped","Degradative vs non-degradative outcome unclear"]},{"year":2020,"claim":"Defined upstream tyrosine-kinase regulation of BCKDK, with Src (Y246) and APN-mediated (S31) phosphorylation enhancing its activity and ERK-directed signaling in cancer.","evidence":"In vitro kinase assays, site-directed mutagenesis, Src KO/KD, proximity ligation in CRC and HCC cells","pmids":["32238881","32457292"],"confidence":"High","gaps":["How phosphorylation alters BCKDK substrate selection unknown","Direct ERK1/2 phosphorylation site not mapped"]},{"year":2021,"claim":"Revealed BCKDK as a compensatory PDC kinase essential for development and as a driver of mitochondrial metabolic reprogramming in cancer.","evidence":"Sequential Pdk/Bckdk knockout mice with PDC activity assays; siRNA/pharmacological BCKDK inhibition in TNBC with respiration and mTORC1 readouts","pmids":["33773101","34526485"],"confidence":"High","gaps":["Direct phosphorylation of PDC E1 by BCKDK not biochemically isolated","Tissue specificity of PDC compensation unclear"]},{"year":2022,"claim":"Confirmed in a second human mutation that BCKDK-mediated BCKDH inactivation is the mechanism of BCAA homeostasis in disease.","evidence":"Transfection of p.Thr334del mutant with BCKDH activity assays and patient metabolite profiling","pmids":["35216372"],"confidence":"Medium","gaps":["Single functional method","Structural effect of deletion not characterized"]},{"year":2023,"claim":"Showed BCKDK can protect substrate proteins from ubiquitination, stabilizing talin1 by blocking TRIM21 to drive focal adhesion and migration.","evidence":"Co-IP, shRNA knockdown, migration assays and lung metastasis model in breast cancer","pmids":["37460470"],"confidence":"Medium","gaps":["Whether kinase activity is required for talin1 protection unclear","Direct vs scaffolding role not separated"]},{"year":2024,"claim":"Expanded the BCKDK substrate repertoire to BCAT1/STUB1, BCLAF1, RNF8, and NDUFS1, establishing roles in cancer metabolism, MYC-driven glycolysis, HR repair, and Complex I stability.","evidence":"In vitro kinase assays, phospho-site mutagenesis, mass spectrometry, ChIP, HR repair assays, subcellular fractionation, and patient-derived iPSC neurons across multiple studies","pmids":["38621458","40442441","40298908","39709505","39170503"],"confidence":"High","gaps":["Determinants of nuclear vs mitochondrial BCKDK localization unknown","Whether substrate phosphorylations occur in the same cell context untested"]},{"year":2024,"claim":"Mapped the post-translational control of BCKDK stability, with Fyn (Y151) activating it and PSMD14 antagonizing TRIM21-mediated degradation.","evidence":"Kinase assays, mutagenesis, deubiquitination assays and knockdowns in GBM cells","pmids":["39170503","41876842"],"confidence":"Medium","gaps":["TRIM21 ubiquitination site on BCKDK not mapped","Interplay of competing PTMs not reconstituted"]},{"year":2024,"claim":"Clarified that the BCKDK inhibitor BT2 has potent BCKDK-independent off-target effects, requiring Bckdk-/- controls for interpretation.","evidence":"Patch-clamp, respiration, equilibrium dialysis and Bckdk-/- and albumin-knockout mice; peer-reviewed and preprint versions","pmids":["38301896","38496495","40348014"],"confidence":"High","gaps":["On-target potency separation from uncoupling not fully quantified for all phenotypes"]},{"year":2024,"claim":"Demonstrated that BCKDK-deficiency pathology arises partly from aberrant catabolic flux, and revealed tissue-specific brain vulnerability via the integrated stress response.","evidence":"Bckdk KO mice with Dbt haploinsufficiency epistasis, behavioral testing, isotope tracing with mass spectrometry imaging and ISR markers","pmids":["38770403","41587643"],"confidence":"Medium","gaps":["Molecular basis of brain-specific ISR activation unresolved","Link between flux abnormality and behavior mechanistically incomplete"]},{"year":2025,"claim":"Established a developmental chromatin role for Bckdk, acting upstream of Phf10/BAF phosphorylation during the maternal-to-zygotic transition.","evidence":"CRISPR-RfxCas13d knockdown, phospho-proteomics and phospho-mimetic Phf10 rescue in zebrafish","pmids":["41254269"],"confidence":"High","gaps":["Conservation in mammals untested","Whether Phf10 is a direct BCKDK substrate not shown by in vitro kinase assay"]},{"year":null,"claim":"How a single kinase partitions between mitochondrial metabolic substrates, cytoplasmic/nuclear signaling substrates, and developmental chromatin targets — and what governs its subcellular localization and substrate choice — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model of localization control","Most non-canonical substrates documented in single studies","Structural basis of diverse substrate recognition unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,4,5,9,12,13,14,19]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,9,13,19]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,19]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,5,11,21]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,5,6,7,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,8,14]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[13]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,8,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,19]}],"complexes":[],"partners":["BCKDHA","MEK","ERK1/2","BCAT1","STUB1","RNF8","BCLAF1","NDUFS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14874","full_name":"Branched-chain alpha-ketoacid dehydrogenase kinase","aliases":["[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial"],"length_aa":412,"mass_kda":46.4,"function":"Serine/threonine-protein kinase component of macronutrients metabolism. Forms a functional kinase and phosphatase pair with PPM1K, serving as a metabolic regulatory node that coordinates branched-chain amino acids (BCAAs) with glucose and lipid metabolism via two distinct phosphoprotein targets: mitochondrial BCKDHA subunit of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex and cytosolic ACLY, a lipogenic enzyme of Krebs cycle (PubMed:24449431, PubMed:29779826, PubMed:37558654). Phosphorylates and inactivates mitochondrial BCKDH complex a multisubunit complex consisting of three multimeric components each involved in different steps of BCAA catabolism: E1 composed of BCKDHA and BCKDHB, E2 core composed of DBT monomers, and E3 composed of DLD monomers. Associates with the E2 component of BCKDH complex and phosphorylates BCKDHA on Ser-337, leading to conformational changes that interrupt substrate channeling between E1 and E2 and inactivates the BCKDH complex (PubMed:29779826, PubMed:37558654). Phosphorylates ACLY on Ser-455 in response to changes in cellular carbohydrate abundance such as occurs during fasting to feeding metabolic transition. Refeeding stimulates MLXIPL/ChREBP transcription factor, leading to increased BCKDK to PPM1K expression ratio, phosphorylation and activation of ACLY that ultimately results in the generation of malonyl-CoA and oxaloacetate immediate substrates of de novo lipogenesis and glucogenesis, respectively (PubMed:29779826). Recognizes phosphosites having SxxE/D canonical motif (PubMed:29779826)","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/O14874/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCKDK","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"TJP2","stoichiometry":4.0},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"HNRNPH1","stoichiometry":0.2},{"gene":"MAP4","stoichiometry":0.2},{"gene":"RBM39","stoichiometry":0.2},{"gene":"SNX9","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCKDK","total_profiled":1310},"omim":[{"mim_id":"614923","title":"BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD","url":"https://www.omim.org/entry/614923"},{"mim_id":"614901","title":"BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE KINASE; BCKDK","url":"https://www.omim.org/entry/614901"},{"mim_id":"611065","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1K; PPM1K","url":"https://www.omim.org/entry/611065"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCKDK"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O14874","domains":[{"cath_id":"1.20.140.20","chopping":"56-219","consensus_level":"high","plddt":91.1484,"start":56,"end":219},{"cath_id":"3.30.565.10","chopping":"224-347_362-402","consensus_level":"high","plddt":92.3727,"start":224,"end":402}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14874","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14874-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14874-F1-predicted_aligned_error_v6.png","plddt_mean":83.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCKDK","jax_strain_url":"https://www.jax.org/strain/search?query=BCKDK"},"sequence":{"accession":"O14874","fasta_url":"https://rest.uniprot.org/uniprotkb/O14874.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14874/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14874"}},"corpus_meta":[{"pmid":"32238881","id":"PMC_32238881","title":"Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32238881","citation_count":64,"is_preprint":false},{"pmid":"24449431","id":"PMC_24449431","title":"Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24449431","citation_count":64,"is_preprint":false},{"pmid":"28501528","id":"PMC_28501528","title":"BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer.","date":"2017","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/28501528","citation_count":56,"is_preprint":false},{"pmid":"37460470","id":"PMC_37460470","title":"BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37460470","citation_count":42,"is_preprint":false},{"pmid":"32457292","id":"PMC_32457292","title":"APN-mediated phosphorylation of BCKDK promotes hepatocellular carcinoma metastasis and proliferation via the ERK signaling pathway.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32457292","citation_count":39,"is_preprint":false},{"pmid":"34526485","id":"PMC_34526485","title":"Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34526485","citation_count":35,"is_preprint":false},{"pmid":"35070754","id":"PMC_35070754","title":"BCKDK alters the metabolism of non-small cell lung cancer.","date":"2021","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35070754","citation_count":34,"is_preprint":false},{"pmid":"26809120","id":"PMC_26809120","title":"Mitochondrial response to the BCKDK-deficiency: Some clues to understand the positive dietary response in this form of autism.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26809120","citation_count":29,"is_preprint":false},{"pmid":"30808755","id":"PMC_30808755","title":"The ubiquitin ligase UBE3B, disrupted in intellectual disability and absent speech, regulates metabolic pathways by targeting BCKDK.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30808755","citation_count":29,"is_preprint":false},{"pmid":"36729635","id":"PMC_36729635","title":"BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36729635","citation_count":24,"is_preprint":false},{"pmid":"33773101","id":"PMC_33773101","title":"BCKDK regulates the TCA cycle through PDC in the absence of PDK family during embryonic development.","date":"2021","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/33773101","citation_count":22,"is_preprint":false},{"pmid":"38734897","id":"PMC_38734897","title":"BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38734897","citation_count":18,"is_preprint":false},{"pmid":"38301896","id":"PMC_38301896","title":"The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38301896","citation_count":18,"is_preprint":false},{"pmid":"35498541","id":"PMC_35498541","title":"BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35498541","citation_count":17,"is_preprint":false},{"pmid":"39025830","id":"PMC_39025830","title":"MAZ-mediated up-regulation of BCKDK reprograms glucose metabolism and promotes growth by regulating glucose-6-phosphate dehydrogenase stability in triple-negative breast cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39025830","citation_count":15,"is_preprint":false},{"pmid":"38621458","id":"PMC_38621458","title":"Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38621458","citation_count":14,"is_preprint":false},{"pmid":"38150655","id":"PMC_38150655","title":"Bckdk-Mediated Branch Chain Amino Acid Metabolism Reprogramming Contributes to Muscle Atrophy during Cancer Cachexia.","date":"2023","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/38150655","citation_count":11,"is_preprint":false},{"pmid":"35205278","id":"PMC_35205278","title":"A Gain-of-Function Mutation on BCKDK Gene and Its Possible Pathogenic Role in Branched-Chain Amino Acid Metabolism.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35205278","citation_count":11,"is_preprint":false},{"pmid":"35216372","id":"PMC_35216372","title":"Novel Loss of Function Variant in BCKDK Causes a Treatable Developmental and Epileptic Encephalopathy.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35216372","citation_count":10,"is_preprint":false},{"pmid":"39709505","id":"PMC_39709505","title":"BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/39709505","citation_count":8,"is_preprint":false},{"pmid":"40442441","id":"PMC_40442441","title":"Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer.","date":"2025","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/40442441","citation_count":8,"is_preprint":false},{"pmid":"30719275","id":"PMC_30719275","title":"Polymorphisms of ACMSD-TMEM163, MCCC1, and BCKDK-STX1B Are Not Associated with Parkinson's Disease in Taiwan.","date":"2019","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/30719275","citation_count":8,"is_preprint":false},{"pmid":"39062842","id":"PMC_39062842","title":"The Role of Branched Chain Ketoacid Dehydrogenase Kinase (BCKDK) in Skeletal Muscle Biology and Pathogenesis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39062842","citation_count":5,"is_preprint":false},{"pmid":"27773658","id":"PMC_27773658","title":"The plasma levels of CST and BCKDK in patients with sepsis.","date":"2016","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/27773658","citation_count":5,"is_preprint":false},{"pmid":"38059302","id":"PMC_38059302","title":"Identification of putative allosteric inhibitors of BCKDK via virtual screening and biological evaluation.","date":"2023","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38059302","citation_count":5,"is_preprint":false},{"pmid":"38770403","id":"PMC_38770403","title":"Partial suppression of BCAA catabolism as a potential therapy for BCKDK deficiency.","date":"2024","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/38770403","citation_count":5,"is_preprint":false},{"pmid":"40298908","id":"PMC_40298908","title":"Nuclear-Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40298908","citation_count":4,"is_preprint":false},{"pmid":"38826327","id":"PMC_38826327","title":"CRISPR-RfxCas13d screening uncovers Bckdk as a post-translational regulator of the maternal-to-zygotic transition in teleosts.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38826327","citation_count":4,"is_preprint":false},{"pmid":"27054191","id":"PMC_27054191","title":"Dataset reporting BCKDK interference in a BCAA-catabolism restricted environment.","date":"2016","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/27054191","citation_count":4,"is_preprint":false},{"pmid":"38496495","id":"PMC_38496495","title":"Off-target depletion of plasma tryptophan by allosteric inhibitors of BCKDK.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38496495","citation_count":3,"is_preprint":false},{"pmid":"37645724","id":"PMC_37645724","title":"The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37645724","citation_count":3,"is_preprint":false},{"pmid":"38736638","id":"PMC_38736638","title":"Computational structural genomics and clinical evidence suggest BCKDK gain-of-function may cause a potentially asymptomatic maple syrup urine disease phenotype.","date":"2024","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/38736638","citation_count":3,"is_preprint":false},{"pmid":"40348014","id":"PMC_40348014","title":"Off-target depletion of plasma tryptophan by allosteric inhibitors of BCKDK.","date":"2025","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40348014","citation_count":2,"is_preprint":false},{"pmid":"41254269","id":"PMC_41254269","title":"CRISPR-RfxCas13d screening uncovers Bckdk as a post-translational regulator of maternal-to-zygotic transition in teleosts.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/41254269","citation_count":2,"is_preprint":false},{"pmid":"40817934","id":"PMC_40817934","title":"BCKDK accelerates the progression of diabetic kidney disease by regulating leucine-mediated metabolic remodelling in renal tubular cells.","date":"2025","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/40817934","citation_count":2,"is_preprint":false},{"pmid":"39170503","id":"PMC_39170503","title":"FYN-mediated phosphorylation of BCKDK at Y151 promotes GBM proliferation by increasing the oncogenic metabolite N-acetyl-L-alanine.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39170503","citation_count":1,"is_preprint":false},{"pmid":"37873402","id":"PMC_37873402","title":"Partial suppression of BCAA catabolism as a potential therapy for BCKDK deficiency.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37873402","citation_count":1,"is_preprint":false},{"pmid":"40661547","id":"PMC_40661547","title":"Opposing effects of systemic and pancreas-specific inhibition of BCKDK on pancreatic carcinogenesis.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40661547","citation_count":0,"is_preprint":false},{"pmid":"41876842","id":"PMC_41876842","title":"Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma.","date":"2026","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/41876842","citation_count":0,"is_preprint":false},{"pmid":"41444608","id":"PMC_41444608","title":"PRSS55 regulates BCAA metabolism and interacts with BCKDK and BCKDHA in mouse testes and sperm.","date":"2025","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/41444608","citation_count":0,"is_preprint":false},{"pmid":"40851941","id":"PMC_40851941","title":"BCKDK gene mutations as a rare condition responsible for comorbid neurodevelopmental delay, autism, and epilepsy: a case series of four patients.","date":"2025","source":"Annals of medicine and surgery (2012)","url":"https://pubmed.ncbi.nlm.nih.gov/40851941","citation_count":0,"is_preprint":false},{"pmid":"33278335","id":"PMC_33278335","title":"Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.","date":"2020","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/33278335","citation_count":0,"is_preprint":false},{"pmid":"41587643","id":"PMC_41587643","title":"A metabolic basis for motor deficits in mice lacking BCKDK.","date":"2026","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41587643","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.22.677943","title":"BCKDK, a novel hypoxia-responsive kinase that exacerbates cerebral ischemia injury","date":"2025-09-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.22.677943","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.16.643501","title":"A hybrid machine learning framework leveraging biophysicochemical insights for scalable discovery of protein-ligand interactions","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.16.643501","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24672,"output_tokens":6102,"usd":0.082773,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14950,"output_tokens":4490,"usd":0.0935,"stage2_stop_reason":"end_turn"},"total_usd":0.176273,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"BCKDK phosphorylates the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKD), inactivating it; loss-of-function mutations in BCKDK (p.L389P and p.R174Gfs1*) result in total loss of kinase activity, undetectable phospho-E1α, increased BCKD activity, and rapid BCAA catabolism, demonstrated in patient-derived fibroblasts.\",\n      \"method\": \"Functional analysis of missense and frameshift mutations in patient fibroblasts; measurement of kinase activity and phospho-E1α levels by western blot\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct kinase activity assay with loss-of-function mutations, orthogonal biochemical readouts (phospho-E1α, BCKD activity), single lab but multiple methods\",\n      \"pmids\": [\"24449431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCKDK promotes colorectal cancer tumorigenesis through direct phosphorylation of MEK, activating the MAPK signaling pathway, independently of its role in BCAA catabolism; this was shown by co-immunoprecipitation and western blot in CRC cells, and inhibited by the BCKDK inhibitor phenyl butyrate.\",\n      \"method\": \"Co-immunoprecipitation, western blot, in vitro kinase assay, cell transformation assays, xenograft models\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct MEK phosphorylation shown by Co-IP and western blot, single lab, limited orthogonal validation of direct kinase activity on MEK\",\n      \"pmids\": [\"28501528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UBE3B (an E3 ubiquitin ligase mutated in Kaufman oculocerebrofacial syndrome) ubiquitinates BCKDK in vivo; BCKDK was identified as a substrate of UBE3B, linking UBE3B loss to perturbation of BCAA metabolic pathways and mitochondrial respiration.\",\n      \"method\": \"In vivo substrate identification (Ube3b knockout mice), Co-immunoprecipitation, metabolomics profiling of plasma and cortex\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and in vivo mouse model with defined metabolic phenotype, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"30808755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Src kinase phosphorylates BCKDK at tyrosine 246 (Y246) in vitro and in cellulo; this phosphorylation enhances BCKDK kinase activity and protein stability, promoting CRC cell migration, invasion, and EMT. Knockdown/knockout of Src reduced BCKDK Y246 phosphorylation.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis (Y246 phospho-dead mutant), Src knockdown/knockout, phosphoproteomics\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, validated in cellulo by Src KO/KD, phosphoproteomics, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"32238881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Aminopeptidase N (APN/CD13) mediates phosphorylation of BCKDK at serine 31 (S31); phosphorylated BCKDK then interacts with ERK1/2 and phosphorylates it, thereby activating the ERK signaling pathway in hepatocellular carcinoma cells.\",\n      \"method\": \"Phosphoproteomics, co-immunoprecipitation, proximity ligation assay, point mutation analysis, western blot, APN knockout in vitro and in vivo\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and proximity ligation assay plus point mutation, multiple methods in single lab\",\n      \"pmids\": [\"32457292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCKDK serves as a compensatory kinase for PDK1-4 (pyruvate dehydrogenase kinases) during embryonic development; in quadruple Pdk knockout embryos, PDC (pyruvate dehydrogenase complex) remained phosphorylated, and additional knockout of Bckdk eliminated PDC phosphorylation, increased PDC activity and pyruvate entry into the TCA cycle, and caused embryonic lethality.\",\n      \"method\": \"Sequential gene knockout (mouse models), PDC activity assay, phosphorylation status assessment by western blot\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic epistasis with in vivo reconstitution-style validation (Pdk total KO + Bckdk KO), direct enzymatic activity assay, multiple KO lines confirming compensatory function\",\n      \"pmids\": [\"33773101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCKDK inhibition in triple-negative breast cancer reduces intracellular BCKAs, downregulates mitochondrial metabolism genes, reduces electron transport chain complex protein expression, oxygen consumption, and ATP production, and upregulates sestrin 2 while decreasing mTORC1 signaling and protein synthesis.\",\n      \"method\": \"Genetic silencing (siRNA/shRNA) and pharmacological inhibition of BCKDK, metabolite measurement, transcriptome analysis, mitochondrial respiration assays, mTORC1 signaling assessment\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological inhibition with multiple functional readouts (metabolites, respiration, signaling), single lab\",\n      \"pmids\": [\"34526485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss-of-function mutation in BCKDK (p.Thr334del) causes hyperactivity of BCKDH and BCAA over-consumption, demonstrated by functional transfection assays in cells; BCKDK phosphorylation-mediated inactivation of BCKDH was thus directly shown to be the molecular mechanism of BCAA homeostasis in human disease.\",\n      \"method\": \"Cell transfection with mutant BCKDK construct, functional BCKDH activity assay, plasma and CSF metabolite measurement\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct enzymatic activity assay in transfected cells, single lab, single method\",\n      \"pmids\": [\"35216372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCKDK inhibits TRIM21-mediated ubiquitination and degradation of talin1 in breast cancer; BCKDK interaction with talin1 was shown, and BCKDK prevented TRIM21-talin1 binding, thereby stabilizing talin1, activating the FAK/MAPK pathway, and promoting focal adhesion assembly and cell migration.\",\n      \"method\": \"Co-immunoprecipitation, western blot, loss-of-function (shRNA knockdown), in vitro migration assays, in vivo lung metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing BCKDK-talin1 and BCKDK-TRIM21 interaction with functional KD and in vivo validation, single lab\",\n      \"pmids\": [\"37460470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability; BCKDK also phosphorylates STUB1 (E3 ubiquitin ligase of BCAT1) at S19, disrupting STUB1-BCAT1 interaction and preventing BCAT1 ubiquitin-mediated degradation, thereby promoting GBM proliferation.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, mass spectrometry, in vivo xenograft experiments\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis at multiple sites, mass spectrometry, Co-IP, and in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"38621458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK interacts with glucose-6-phosphate dehydrogenase (G6PD) and increases flux through the pentose phosphate pathway; forced G6PD expression rescued growth defects in BCKDK-deficient TNBC cells, placing BCKDK upstream of G6PD in metabolic reprogramming.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, isotope tracer studies, immunofluorescence, rescue (G6PD overexpression), cell viability assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, isotope tracing, and genetic rescue in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39025830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK interacts with the NDUFS1 subunit of mitochondrial Complex I to stabilize its function; loss of BCKDK disrupts this interaction, leading to Complex I destabilization, reduced membrane potential, increased ROS, and promotion of α-synuclein oligomerization and aggregation in dopaminergic neurons.\",\n      \"method\": \"Co-immunoprecipitation, mitochondrial membrane potential assay, ROS measurement, BCKDK knockdown/restoration in neuron-like cells and patient-derived iPS-derived dopaminergic neurons\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying NDUFS1 interaction, rescue experiments restoring Complex I activity, validated in patient-derived cells, single lab\",\n      \"pmids\": [\"39709505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK interacts with BCLAF1 and promotes its phosphorylation at serine 285; this modification enables BCLAF1 to bind the MYC promoter and enhance MYC transcription, which upregulates hexokinase 2 (HK2) to promote aerobic glycolysis and lung cancer progression and Trametinib resistance.\",\n      \"method\": \"Co-immunoprecipitation, western blot, chromatin immunoprecipitation, luciferase reporter assay, point mutation, RNA sequencing, cell-based functional assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, luciferase, and phospho-site mutation in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"40442441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Nuclear-localized BCKDK phosphorylates RNF8 at Ser157, preventing ubiquitin-mediated degradation of RAD51, thereby facilitating homologous recombination repair (HRR) and promoting resistance to DNA damage-inducing therapy in breast cancer; this function is independent of BCKDK's metabolic role.\",\n      \"method\": \"Subcellular fractionation/localization (nuclear BCKDK), Co-IP, site-directed mutagenesis, RAD51 ubiquitination assay, HR repair functional assay, pharmacological inhibition\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation of RNF8 shown with site mutagenesis, Co-IP, and functional HR assay, nuclear localization by fractionation, single lab\",\n      \"pmids\": [\"40298908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Fyn tyrosine kinase phosphorylates BCKDK at Y151, increasing its catalytic activity and protein stability, promoting GBM cell proliferation; elevated BCKDK also increases N-acetyl-L-alanine (NAAL) levels, which activates ERK signaling and promotes proliferation; silencing BCKDK increases ACY1 expression.\",\n      \"method\": \"In vitro and in vivo kinase assay, site-directed mutagenesis (Y151), metabolite profiling, western blot, tumor xenograft model\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with mutagenesis, metabolite profiling, single lab\",\n      \"pmids\": [\"39170503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The BCKDK inhibitor BT2 acts as a mitochondrial uncoupler independently of its inhibitory effect on BCKDK; BT2 increases proton conductance across the mitochondrial inner membrane, lowering mitochondrial ROS production and de novo lipogenesis, as confirmed using patch-clamp electrophysiology and oxygen consumption measurements, and was active even in Bckdk-/- animals.\",\n      \"method\": \"Oxygen consumption measurement, mitochondrial membrane potential assay, patch-clamp electrophysiology, Bckdk knockout mouse model, de novo lipogenesis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal direct methods (patch-clamp, respiration, membrane potential), confirmed in knockout animals to isolate off-target effect, single lab but rigorous multi-method study\",\n      \"pmids\": [\"38301896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PSMD14 deubiquitinase directly interacts with and deubiquitinates BCKDK, antagonizing TRIM21-mediated proteasomal degradation of BCKDK, thereby stabilizing BCKDK protein levels in GBM cells.\",\n      \"method\": \"Co-immunoprecipitation, deubiquitination assay, PSMD14 knockdown, western blot\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and deubiquitination assay identifying PSMD14-BCKDK interaction and TRIM21 as E3 ligase, single lab\",\n      \"pmids\": [\"41876842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BT2 (a BCKDK allosteric inhibitor) activates BCAA oxidation via inhibition of BCKDK, but also independently reduces plasma tryptophan by binding serum albumin and displacing tryptophan, releasing it for catabolism to kynurenine; this was demonstrated using Bckdk-/- mice (where BT2 could not activate BCAA oxidation but still depleted tryptophan), equilibrium dialysis, and albumin-deficient mice.\",\n      \"method\": \"Bckdk-/- mouse model, equilibrium dialysis, albumin-knockout mice, metabolite profiling\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous use of Bckdk-/- mice to isolate on-target vs off-target effects, orthogonal validation with equilibrium dialysis and albumin-KO mice, mechanistically definitive\",\n      \"pmids\": [\"38496495\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BT2 activates BCAA oxidation through BCKDK inhibition, but also independently reduces plasma tryptophan by binding serum albumin and displacing tryptophan; this off-target effect was confirmed in Bckdk-/- mice by equilibrium dialysis and albumin-deficient mice (peer-reviewed version of preprint 38496495).\",\n      \"method\": \"Bckdk-/- mouse model, equilibrium dialysis, albumin-knockout mice, plasma metabolite profiling\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods, confirmed in multiple genetic mouse models, peer-reviewed replication of preprint findings\",\n      \"pmids\": [\"40348014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In zebrafish, Bckdk acts as a post-translational regulator of the maternal-to-zygotic transition (MZT); Bckdk depletion reduces phosphorylation of Phf10/Baf45a (a BAF chromatin remodeling subunit), and expression of a phospho-mimetic Phf10 rescued epiboly defects and ZGA abnormalities caused by bckdk knockdown, placing BCKDK upstream of Phf10-mediated chromatin remodeling during MZT.\",\n      \"method\": \"CRISPR-RfxCas13d mRNA knockdown screen in zebrafish, phospho-proteomics, phf10 mRNA knockdown, phospho-mimetic Phf10 rescue, H3K27ac measurement\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — epistasis via phospho-mimetic rescue, phospho-proteomics identifying substrate, functional developmental readout, multiple orthogonal methods in single study\",\n      \"pmids\": [\"41254269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRSS55 interacts with BCKDK and its substrate BCKDHA in mouse testes/sperm, as validated by co-immunoprecipitation and LC-MS/MS; loss of Prss55 results in accumulation of BCAAs in testes, suggesting PRSS55 modulates BCKDK-mediated BCAA catabolism in the context of sperm mitochondrial function.\",\n      \"method\": \"Co-immunoprecipitation, LC-MS/MS, Prss55-/- mouse model, metabolomics, mitochondrial function assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and LC-MS/MS validating interaction, metabolomics and functional assays in KO mouse, single lab\",\n      \"pmids\": [\"41444608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In BCKDK-deficient patient fibroblasts, loss of BCKDK increases superoxide anion production (2-fold), reduces ATP-linked respiration and intracellular ATP levels (to ~60%), and causes mitochondrial hyperfusion associated with changes in OPA1 and mitofusin 2/MFN2 forms; BCKDK knockdown in control fibroblasts recapitulated these mitochondrial phenotypes.\",\n      \"method\": \"Bioenergetics assays (oxygen consumption, ATP measurement), superoxide measurement, ultrastructural analysis (electron microscopy), western blot (OPA1, MFN2), siRNA knockdown\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple direct mitochondrial functional assays in patient cells and siRNA knockdown confirmation, single lab\",\n      \"pmids\": [\"26809120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In BCKDK-deficient mice, genetic re-regulation of BCAA catabolism via Dbt haploinsufficiency (reducing downstream catabolic flux) partially rescues biochemical and behavioral phenotypes, demonstrating that aberrant flux through the BCAA catabolic pathway (not just BCAA insufficiency) contributes to pathology.\",\n      \"method\": \"Mouse model of BCKDK deficiency, Dbt haploinsufficiency genetic epistasis, behavioral testing, plasma metabolite measurement\",\n      \"journal\": \"Molecular genetics and metabolism reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in mouse model with biochemical and behavioral rescue readouts, single lab\",\n      \"pmids\": [\"38770403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In BCKDK-deficient mouse brains (but not skeletal muscle), fasting activates the integrated stress response (ISR) with upregulation of Atf4 and its targets including Slc7a5; stable isotope tracing showed lower BCAA-derived nitrogen delivery to brain glutamate in BCKDK KO mice, demonstrating a brain-specific metabolic vulnerability.\",\n      \"method\": \"Bckdk KO mouse model, stable isotope tracing with mass spectrometry imaging, protein synthesis measurement, ISR marker quantification (ATF4, target genes), mTORC1 signaling assessment\",\n      \"journal\": \"The Journal of nutritional biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isotope tracing with mass spectrometry imaging, KO mouse model, multiple orthogonal pathway readouts, single lab\",\n      \"pmids\": [\"41587643\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCKDK is a mitochondria-associated kinase that canonically phosphorylates and inactivates the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby restraining BCAA catabolism; beyond this metabolic role, BCKDK also phosphorylates MEK, ERK1/2, RNF8, BCAT1, STUB1, BCLAF1, and Phf10 to regulate MAPK signaling, homologous recombination repair, chromatin remodeling during embryonic development, and cancer cell metabolism, and is itself regulated by phosphorylation from upstream kinases (Src at Y246, Fyn at Y151, APN-mediated at S31) and by ubiquitination via TRIM21 (antagonized by PSMD14), with its protein stability and activity controlled by these post-translational modifications.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCKDK is a mitochondria-associated protein kinase that controls branched-chain amino acid (BCAA) catabolism by phosphorylating and inactivating the E1\\u03b1 subunit of the branched-chain \\u03b1-keto acid dehydrogenase complex (BCKDH), with loss-of-function mutations abolishing E1\\u03b1 phosphorylation, derepressing BCKDH activity, and driving rapid BCAA over-consumption in patients [#0, #7]. Its metabolic reach extends beyond BCKDH: BCKDK acts as a compensatory kinase for the pyruvate dehydrogenase complex during embryogenesis, and its combined loss with the pyruvate dehydrogenase kinases eliminates PDC phosphorylation and is embryonic-lethal [#5]. Loss of BCKDK perturbs mitochondrial bioenergetics, increasing superoxide production, lowering ATP-linked respiration, and altering mitochondrial morphology [#21], and BCKDK physically stabilizes the Complex I subunit NDUFS1, with its loss promoting \\u03b1-synuclein aggregation in dopaminergic neurons [#11]. In disease tissue, BCKDK functions as a signaling kinase independent of BCAA metabolism, directly phosphorylating MEK and ERK1/2 to activate MAPK signaling [#1, #4], phosphorylating BCAT1 and STUB1 to stabilize BCAT1 and drive glioblastoma growth [#9], phosphorylating BCLAF1 to enhance MYC-driven glycolysis [#12], and \\u2014 from a nuclear pool \\u2014 phosphorylating RNF8 to protect RAD51 and promote homologous recombination repair [#13]. BCKDK is itself regulated by post-translational modification: Src (Y246) and Fyn (Y151) phosphorylation enhance its activity and stability [#3, #14], UBE3B and TRIM21 ubiquitinate it while PSMD14 deubiquitinates and stabilizes it [#2, #16], and BCKDK reciprocally protects substrates such as talin1 from TRIM21-mediated degradation [#8]. The small-molecule inhibitors BT2 and phenylbutyrate inhibit BCKDK, but BT2 also acts off-target as a mitochondrial uncoupler and albumin-tryptophan displacer independently of BCKDK [#15, #18]. A zebrafish study additionally places Bckdk upstream of Phf10/BAF chromatin remodeling during the maternal-to-zygotic transition [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that BCKDK is the physiological kinase that restrains BCAA catabolism by phosphorylating and inactivating BCKDH E1\\u03b1, resolving how BCAA homeostasis is set in humans.\",\n      \"evidence\": \"Functional analysis of loss-of-function mutations (p.L389P, p.R174Gfs1*) in patient fibroblasts with kinase activity and phospho-E1\\u03b1 readouts\",\n      \"pmids\": [\"24449431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address non-metabolic substrates\", \"No structural basis for E1\\u03b1 recognition\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed BCKDK loss has broad mitochondrial consequences beyond BCAA flux, linking it to redox balance, bioenergetics, and mitochondrial dynamics.\",\n      \"evidence\": \"Bioenergetics, superoxide and EM analysis in BCKDK-deficient patient fibroblasts plus siRNA knockdown\",\n      \"pmids\": [\"26809120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking BCKDK loss to OPA1/MFN2 changes unresolved\", \"Whether effects are metabolic or direct unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"First evidence that BCKDK has a metabolism-independent signaling function, directly phosphorylating MEK to activate MAPK in cancer.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, transformation and xenograft assays in CRC cells\",\n      \"pmids\": [\"28501528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MEK phosphorylation not independently confirmed\", \"Phospho-site on MEK not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified BCKDK as a ubiquitination substrate of UBE3B, establishing post-translational control of its abundance and a disease link.\",\n      \"evidence\": \"Reciprocal Co-IP and metabolomics in Ube3b knockout mice\",\n      \"pmids\": [\"30808755\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site not mapped\", \"Degradative vs non-degradative outcome unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined upstream tyrosine-kinase regulation of BCKDK, with Src (Y246) and APN-mediated (S31) phosphorylation enhancing its activity and ERK-directed signaling in cancer.\",\n      \"evidence\": \"In vitro kinase assays, site-directed mutagenesis, Src KO/KD, proximity ligation in CRC and HCC cells\",\n      \"pmids\": [\"32238881\", \"32457292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation alters BCKDK substrate selection unknown\", \"Direct ERK1/2 phosphorylation site not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed BCKDK as a compensatory PDC kinase essential for development and as a driver of mitochondrial metabolic reprogramming in cancer.\",\n      \"evidence\": \"Sequential Pdk/Bckdk knockout mice with PDC activity assays; siRNA/pharmacological BCKDK inhibition in TNBC with respiration and mTORC1 readouts\",\n      \"pmids\": [\"33773101\", \"34526485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of PDC E1 by BCKDK not biochemically isolated\", \"Tissue specificity of PDC compensation unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed in a second human mutation that BCKDK-mediated BCKDH inactivation is the mechanism of BCAA homeostasis in disease.\",\n      \"evidence\": \"Transfection of p.Thr334del mutant with BCKDH activity assays and patient metabolite profiling\",\n      \"pmids\": [\"35216372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single functional method\", \"Structural effect of deletion not characterized\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed BCKDK can protect substrate proteins from ubiquitination, stabilizing talin1 by blocking TRIM21 to drive focal adhesion and migration.\",\n      \"evidence\": \"Co-IP, shRNA knockdown, migration assays and lung metastasis model in breast cancer\",\n      \"pmids\": [\"37460470\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether kinase activity is required for talin1 protection unclear\", \"Direct vs scaffolding role not separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the BCKDK substrate repertoire to BCAT1/STUB1, BCLAF1, RNF8, and NDUFS1, establishing roles in cancer metabolism, MYC-driven glycolysis, HR repair, and Complex I stability.\",\n      \"evidence\": \"In vitro kinase assays, phospho-site mutagenesis, mass spectrometry, ChIP, HR repair assays, subcellular fractionation, and patient-derived iPSC neurons across multiple studies\",\n      \"pmids\": [\"38621458\", \"40442441\", \"40298908\", \"39709505\", \"39170503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of nuclear vs mitochondrial BCKDK localization unknown\", \"Whether substrate phosphorylations occur in the same cell context untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped the post-translational control of BCKDK stability, with Fyn (Y151) activating it and PSMD14 antagonizing TRIM21-mediated degradation.\",\n      \"evidence\": \"Kinase assays, mutagenesis, deubiquitination assays and knockdowns in GBM cells\",\n      \"pmids\": [\"39170503\", \"41876842\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRIM21 ubiquitination site on BCKDK not mapped\", \"Interplay of competing PTMs not reconstituted\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Clarified that the BCKDK inhibitor BT2 has potent BCKDK-independent off-target effects, requiring Bckdk-/- controls for interpretation.\",\n      \"evidence\": \"Patch-clamp, respiration, equilibrium dialysis and Bckdk-/- and albumin-knockout mice; peer-reviewed and preprint versions\",\n      \"pmids\": [\"38301896\", \"38496495\", \"40348014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"On-target potency separation from uncoupling not fully quantified for all phenotypes\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that BCKDK-deficiency pathology arises partly from aberrant catabolic flux, and revealed tissue-specific brain vulnerability via the integrated stress response.\",\n      \"evidence\": \"Bckdk KO mice with Dbt haploinsufficiency epistasis, behavioral testing, isotope tracing with mass spectrometry imaging and ISR markers\",\n      \"pmids\": [\"38770403\", \"41587643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of brain-specific ISR activation unresolved\", \"Link between flux abnormality and behavior mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established a developmental chromatin role for Bckdk, acting upstream of Phf10/BAF phosphorylation during the maternal-to-zygotic transition.\",\n      \"evidence\": \"CRISPR-RfxCas13d knockdown, phospho-proteomics and phospho-mimetic Phf10 rescue in zebrafish\",\n      \"pmids\": [\"41254269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conservation in mammals untested\", \"Whether Phf10 is a direct BCKDK substrate not shown by in vitro kinase assay\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single kinase partitions between mitochondrial metabolic substrates, cytoplasmic/nuclear signaling substrates, and developmental chromatin targets \\u2014 and what governs its subcellular localization and substrate choice \\u2014 remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model of localization control\", \"Most non-canonical substrates documented in single studies\", \"Structural basis of diverse substrate recognition unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 9, 12, 13, 14, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 9, 13, 19]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 5, 11, 21]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 5, 6, 7, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 8, 14]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 8, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BCKDHA\", \"MEK\", \"ERK1/2\", \"BCAT1\", \"STUB1\", \"RNF8\", \"BCLAF1\", \"NDUFS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}